Acadia Pharmaceuticals (ACAD) Work In Process (2018 - 2026)

Acadia Pharmaceuticals has reported Work In Process for 9 years, with the latest figure at $80.7 million in Q1 2026.

• For the quarter ending Q1 2026, Work In Process rose 0.87% year-over-year to $80.7 million; the trailing twelve-month figure through Mar 2026 stood at $80.7 million (up 0.87% YoY), and the FY2025 full-year result was $76.7 million, up 9.98% from the prior year.
• Work In Process for Q1 2026 stood at $80.7 million, up from $76.7 million in the prior quarter.
• The five-year high for Work In Process was $84.4 million in Q2 2025, with the low at $4.6 million in Q3 2023.
• Average Work In Process over 5 years is $32.8 million, with a median of $6.2 million recorded in 2022.
• Year-over-year, Work In Process dropped 27.24% in 2022 and surged 1406.94% in 2024.
• Tracing ACAD's Work In Process over 5 years: stood at $4.9 million in 2022, then declined by 6.01% to $4.6 million in 2023, then surged by 1406.94% to $69.7 million in 2024, then climbed by 9.98% to $76.7 million in 2025, then rose by 5.23% to $80.7 million in 2026.
• The last three Work In Process figures came in at $80.7 million (Q1 2026), $76.7 million (Q4 2025), and $76.9 million (Q3 2025), per Business Quant data.

Peer Comparison